Investigation of the efficacy and safty of antimuscalinics and beta-stimulant in subjects with overactive bladder

Investigation of the efficacy and safty of antimuscalinics and beta-stimulant in subjects with overactive bladder - Efficacy and safty of antimuscalinics and beta-stimulant in subjects with overactive bladder

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009962

Enrollment

200

Registered

2013-02-10

Start date

2013-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive bladder

Interventions

BPH(n:50):Imidafenacin(0.2mg) Mirabegron(50mg) BPH(n:50):Mirabegron(50mg) Imidafenacin(0.2mg) iOAB(n:50):Solifenacin(5mg) Mirabegron(50mg) iOAB(n:50):Mirabegron(50mg) Solifenacin(5mg)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed as enlargement of prostate and remain the symptoms of over active bladder after the treatment of alpha1 blocking agents. 2. Patients diagnosed as idiopathic overactive bladder.

Exclusion criteria

Exclusion criteria: Patients in fertile age and patients with a serious heart trouble, severe liver function disorder, closed-angle glaucoma, pyloric part obstruction, duodenal obstruction, enterocleisis, paralytic ileus, gastric atony, intestinal atony, myasthenia gravis and patients under the flecainide acetate dosage, the propafenone hydrochloride dosage.

Design outcomes

Primary

Measure	Time frame
Comparative analysis in changes of overactive bladder symptoms by the administration of antimuscarinic agents and beta-stimulants.	—

Countries

Japan

Contacts

Public ContactTakumi Yamada

Saitama Medical Center, Saitama Medical University Urology

t_yamada@saitama-med.ac.jp049-228-3422

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026